1. Gates B. Responding to Covid-19 - a once-in-a-century pandemic? N Engl J Med. 2020;382:1677–9.
2. Ekins S, Mottin M, Ramos PRPS, Sousa BKP, Neves BJ, Foil DH, Zorn KM, Braga RC, Coffee M, Southan C, Puhl AC, Andrade CH. Déjà vu: Stimulating Open Drug Discovery for SARS-CoV-2. Drug Discov Today. 2020; Apr 19:S1359-6446(20)30145-8. https://doi.org/10.1016/j.drudis.2020.03.019.
3. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–2.
4. Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Available from: https://www.biorxiv.org/content/10.1101/2020.03.20.999730v1.
5. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, Duan Y, Yu J, Wang L, Yang K, liu F, Jiang R, Yang X, You T, Liu X, Yang X, Bai F, Liu H, Liu X, Guddat LW, Xu W, Xiao G, Qin C, Shi Z, Jiang HY, Rao Z, yang H. Structure of Mpro from 1 COVID-19 virus and discovery of its inhibitors. Available from: https://www.biorxiv.org/content/10.1101/2020.02.26.964882v2.